학술논문
Repurposing the oncolytic virus VSV∆51M as a COVID-19 vaccine.
Document Type
Academic Journal
Author
Alkayyal AA; Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.; Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; Darwish M; Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; Ajina R; Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.; Alabbas SY; Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; Alotaibi MA; Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; Alsofyani A; Department of Cellular Therapy and Cancer Research, King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.; King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.; Bokhamseen M; Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; Hakami M; Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; Albaradie OA; Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.; Moglan AM; Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.; Hala S; King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.; Infectious Disease Research Department, King Abdullah International Medical Research Centre, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.; Alsahafi AF; King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.; Infectious Disease Research Department, King Abdullah International Medical Research Centre, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.; Zakri S; King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.; Infectious Disease Research Department, King Abdullah International Medical Research Centre, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.; Almuzaini A; Experimental Medicine Department, King Abdullah International Medical Research Centre, Jeddah, Saudi Arabia.; Alsharari K; Experimental Medicine Department, King Abdullah International Medical Research Centre, Jeddah, Saudi Arabia.; Kaboha F; Experimental Medicine Department, King Abdullah International Medical Research Centre, Jeddah, Saudi Arabia.; Taher MY; College of Applied Medical Sciences, Taibah University, Madinah, Saudi Arabia.; Zein HS; Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.; Alroqi F; Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; Department of Immunology, Ministry of the National Guard-Health Affairs, Riyadh, Saudi Arabia.; King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.; Mahmoud AB; College of Applied Medical Sciences, Taibah University, Madinah, Saudi Arabia.; Strategic Research and Innovation Laboratories, Taibah University, Madinah, Saudi Arabia.; Immunology Research Program, King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
Source
Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101632513 Publication Model: eCollection Cited Medium: Print ISSN: 2296-4185 (Print) Linking ISSN: 22964185 NLM ISO Abbreviation: Front Bioeng Biotechnol Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2296-4185
Abstract
The coronavirus disease 2019 (COVID-19) pandemic imposes an urgent and continued need for the development of safe and cost-effective vaccines to induce preventive responses for limiting major outbreaks around the world. To combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we repurposed the VSV∆51M oncolytic virus platform to express the spike receptor-binding domain (RBD) antigen. In this study, we report the development and characterization of the VSV∆51M-RBD vaccine. Our findings demonstrate successful expression of the RBD gene by the VSV∆51M-RBD virus, inducing anti-RBD responses without attenuating the virus. Moreover, the VSV∆51M-RBD vaccine exhibited safety, immunogenicity, and the potential to serve as a safe and effective alternative or complementary platform to current COVID-19 vaccines.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2023 Alkayyal, Darwish, Ajina, Alabbas, Alotaibi, Alsofyani, Bokhamseen, Hakami, Albaradie, Moglan, Hala, Alsahafi, Zakri, Almuzaini, Alsharari, Kaboha, Taher, Zein, Alroqi and Mahmoud.)
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2023 Alkayyal, Darwish, Ajina, Alabbas, Alotaibi, Alsofyani, Bokhamseen, Hakami, Albaradie, Moglan, Hala, Alsahafi, Zakri, Almuzaini, Alsharari, Kaboha, Taher, Zein, Alroqi and Mahmoud.)